Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Biogen
Sort By
Newest First
1 / 1
1 / 1
Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder
Sage Therapeutics
PR-M06-21-023
Jun 18, 2021
Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra®
Biogen
PR-M06-21-010
Jun 08, 2021
FDA Approval
FDA Grants Accelerated Approval for Aduhelm™ as the First and Only Alzheimer’s Disease Treatment to Address a Defining Pathology of the Disease
Biogen
PR-M06-21-015
Jun 08, 2021
Collaboration
Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform
Biogen
PR-M05-21-017-979
May 26, 2021
Licensing Agreement
Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder
Massachusetts Eye and Ear
PR-M07-20-NI-001
Jul 03, 2020
Clinical Study
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Biogen
PR-M10-19-NI-031
Oct 22, 2019
Acquisition
Biogen Moves into Gene Therapy with Nightstar Buy
Emilie Branch
Pharma's Almanac
PAO-M03-19-NI-014
Mar 05, 2019
RNA Splicing
Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
Biogen
PR-M01-19-NI-032
Jan 11, 2019
Study Results
Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease
Eisai
PR-M07-18-NI-103
Jul 31, 2018
Investment
Biogen Exercises Option to Increase Ownership in Samsung Bioepis
Biogen
PR-M07-18-NI-018
Jul 06, 2018
Strategic Collaboration
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
Biogen
PR-M04-18-NI-90
Apr 25, 2018
Acquistion
Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia
Biogen
PR-M03-18-NI-049
Mar 14, 2018